EP2440246A4 - Egfr and par2 regulation of intestinal permeability - Google Patents
Egfr and par2 regulation of intestinal permeabilityInfo
- Publication number
- EP2440246A4 EP2440246A4 EP10786502.4A EP10786502A EP2440246A4 EP 2440246 A4 EP2440246 A4 EP 2440246A4 EP 10786502 A EP10786502 A EP 10786502A EP 2440246 A4 EP2440246 A4 EP 2440246A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- par2
- egfr
- regulation
- intestinal permeability
- intestinal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biochemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18566209P | 2009-06-10 | 2009-06-10 | |
PCT/US2010/001670 WO2010144140A2 (en) | 2009-06-10 | 2010-06-10 | Egfr and par2 regulation of intestinal permeability |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2440246A2 EP2440246A2 (en) | 2012-04-18 |
EP2440246A4 true EP2440246A4 (en) | 2013-08-28 |
Family
ID=43309408
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP10786502.4A Ceased EP2440246A4 (en) | 2009-06-10 | 2010-06-10 | Egfr and par2 regulation of intestinal permeability |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP2440246A4 (en) |
JP (1) | JP2012529508A (en) |
KR (1) | KR20120031496A (en) |
CN (2) | CN102481362A (en) |
AU (1) | AU2010259213A1 (en) |
CA (1) | CA2765075A1 (en) |
WO (1) | WO2010144140A2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120107329A1 (en) * | 2009-06-10 | 2012-05-03 | University Of Maryland, Baltimore | EGFR and PAR2 Regulation of Intestinal Permeability |
EP4187246A4 (en) | 2020-07-22 | 2024-02-07 | FUJIFILM Corporation | Method for assisting diagnosis of inflammatory bowel disease |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060040883A1 (en) * | 2004-05-14 | 2006-02-23 | The Regents Of The University Of California | Methods for treating cancer using anti-Wnt2 monoclonal antibodies and siRNA |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6458925B1 (en) * | 1998-08-03 | 2002-10-01 | University Of Maryland, Baltimore | Peptide antagonists of zonulin and methods for use of the same |
AU2002211658A1 (en) * | 2000-10-13 | 2002-04-22 | Uab Research Foundation | Human anti-epidermal growth factor receptor single-chain antibodies |
US7611480B2 (en) * | 2003-04-24 | 2009-11-03 | Levy Mark M | Gastrointestinal bioreactor |
JP2008545951A (en) * | 2005-05-13 | 2008-12-18 | ユニバーシティ オブ メリーランド, ボルチモア | Method for assessing the effectiveness of treatment regimens by determining zonulin |
-
2010
- 2010-06-10 EP EP10786502.4A patent/EP2440246A4/en not_active Ceased
- 2010-06-10 AU AU2010259213A patent/AU2010259213A1/en not_active Abandoned
- 2010-06-10 CN CN2010800318809A patent/CN102481362A/en active Pending
- 2010-06-10 KR KR1020127000353A patent/KR20120031496A/en not_active Application Discontinuation
- 2010-06-10 WO PCT/US2010/001670 patent/WO2010144140A2/en active Application Filing
- 2010-06-10 JP JP2012514946A patent/JP2012529508A/en active Pending
- 2010-06-10 CA CA2765075A patent/CA2765075A1/en not_active Abandoned
- 2010-06-10 CN CN201510201412.6A patent/CN104940927A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060040883A1 (en) * | 2004-05-14 | 2006-02-23 | The Regents Of The University Of California | Methods for treating cancer using anti-Wnt2 monoclonal antibodies and siRNA |
Non-Patent Citations (9)
Title |
---|
"AGA Abstracts S1448-M1084", GASTROENTEROLOGY, ELSEVIER, PHILADELPHIA, PA, vol. 126, no. 4, 1 April 2004 (2004-04-01), pages A249 - A249, XP022471374, ISSN: 0016-5085, DOI: 10.1016/S0016-5085(04)80010-6 * |
M C ARRIETA ET AL: "Reducing small intestinal permeability attenuates colitis in the IL10 gene-deficient mouse", GUT, vol. 58, no. 1, 1 October 2008 (2008-10-01), pages 41 - 48, XP055071471, ISSN: 0017-5749, DOI: 10.1136/gut.2008.150888 * |
PAPP M. ET AL: "Haptoglobin Polymorphism: A Novel Genetic Risk Factor for Celiac Disease Development and Its Clinical Manifestations", CLINICAL CHEMISTRY, vol. 54, no. 4, 1 April 2008 (2008-04-01), pages 697 - 704, XP055105643, ISSN: 0009-9147, DOI: 10.1373/clinchem.2007.098780 * |
PAPP M. ET AL: "S1256 Haptoglobin Polymorphism: A Novel Genetic Risk Factor for Celiac Disease Development and Its Clinical Manifestations", GASTROENTEROLOGY, ELSEVIER, PHILADELPHIA, PA, vol. 134, no. 4, 1 April 2008 (2008-04-01), pages A-211 - A-212, XP023432775, ISSN: 0016-5085, [retrieved on 20080401], DOI: 10.1016/S0016-5085(08)60978-6 * |
SAGIV E ET AL: "992 Unraveling Novel Mechanisms By Which the CD24 Oncogene Serves As a Target for Colorectal and Pancreatic Cancer Treatment, Via Down-Regulation By Monoclonal Antibodies or SIRNA", GASTROENTEROLOGY, ELSEVIER, PHILADELPHIA, PA, vol. 134, no. 4, 1 April 2008 (2008-04-01), pages A - 149, XP023432489, ISSN: 0016-5085, [retrieved on 20080401], DOI: 10.1016/S0016-5085(08)60692-7 * |
SANDRO DRAGO ET AL: "Gliadin, zonulin and gut permeability: Effects on celiac and non-celiac intestinal mucosa and intestinal cell lines", SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, vol. 41, no. 4, 1 January 2006 (2006-01-01), pages 408 - 419, XP055105654, ISSN: 0036-5521, DOI: 10.1080/00365520500235334 * |
SAPONE A ET AL: "Inhibition of the zonulin pathway blocks the progression from pre-clinical autoimmunity to type 1 diabetes in BB/Wor rats", DIGESTIVE AND LIVER DISEASE, W.B. SAUNDERS, GB, vol. 38, 1 April 2006 (2006-04-01), pages S87 - S87, XP025948595, ISSN: 1590-8658, [retrieved on 20060401], DOI: 10.1016/S1590-8658(06)80231-8 * |
SAPONE A ET AL: "Serum zonulin and intestinal permeability before and after a gluten-containing meal in both type 1 diabetes and their relatives", DIGESTIVE AND LIVER DISEASE, W.B. SAUNDERS, GB, vol. 38, 1 April 2006 (2006-04-01), pages S75 - S75, XP025948561, ISSN: 1590-8658, [retrieved on 20060401], DOI: 10.1016/S1590-8658(06)80197-0 * |
SMECUOL ET AL: "Permeability, zonulin production, and enteropathy in dermatitis herpetiformis", CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, AMERICAN GASTROENTEROLOGICAL ASSOCIATION, US, vol. 3, no. 4, 1 April 2005 (2005-04-01), pages 335 - 341, XP005120726, ISSN: 1542-3565, DOI: 10.1016/S1542-3565(04)00778-5 * |
Also Published As
Publication number | Publication date |
---|---|
CN104940927A (en) | 2015-09-30 |
CN102481362A (en) | 2012-05-30 |
KR20120031496A (en) | 2012-04-03 |
WO2010144140A2 (en) | 2010-12-16 |
CA2765075A1 (en) | 2010-12-16 |
AU2010259213A1 (en) | 2012-01-19 |
WO2010144140A3 (en) | 2011-05-19 |
WO2010144140A4 (en) | 2011-07-14 |
WO2010144140A8 (en) | 2012-01-26 |
JP2012529508A (en) | 2012-11-22 |
EP2440246A2 (en) | 2012-04-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUS2100009I1 (en) | Combution of halauxifen-methyl and piroxsulam | |
EG27167A (en) | Microemulsifiers and methods of making and using same | |
EP2556799A4 (en) | Tissue clamp production method and tissue clamp | |
EP2279291A4 (en) | Coferons and methods of making and using them | |
EP2424357A4 (en) | Treatment of neurodegeneration and neuroinflammation | |
EP2637502A4 (en) | Mutant-selective egfr inhibitors and uses thereof | |
EP2485678A4 (en) | Coferons and methods of making and using them | |
ZA201109034B (en) | Aminopyrrolidinone derivatives and uses thereof | |
IL213974A0 (en) | Isoxazole-isoxazole and isoxazole-isothiazole derivatives | |
IL236830A0 (en) | Diazahomoadamantane derivatives and methods of use thereof | |
EP2561072A4 (en) | Nanozymes, methods of making nanozymes, and methods of using nanozymes | |
GB0915515D0 (en) | Treatment of vasculoproliferative conditions | |
GB0908507D0 (en) | Hyperbaric dessing and method | |
EP2456948A4 (en) | Wired conduit segment and method of making same | |
EP2578153A4 (en) | Audiometer and method thereof | |
GB2486994B (en) | Optically variable devices and method of manufacture | |
IL206491A0 (en) | Treatment of produce | |
IL197655A0 (en) | Emulsions and methods of their production | |
PL2264358T3 (en) | Luminaire and lightband | |
HK1178526A1 (en) | Tertiary 8-hydroxyquinoline-7-carboxamide derivatives and uses thereof 8--7- | |
EP2490541A4 (en) | 2-substituted-ethynylthiazole derivatives and uses of same | |
PT2563806E (en) | Human leukolectins and uses thereof | |
EP2791360A4 (en) | Egfr and par2 regulation of intestinal permeability | |
GB201115521D0 (en) | Colorant-polyesters and methods of producing colorant-polyesters | |
EP2637639A4 (en) | Transfer resistant cosmetics and method of making |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20120106 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20130725 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 3/10 20060101ALI20130719BHEP Ipc: A61K 39/395 20060101AFI20130719BHEP Ipc: A61P 37/00 20060101ALI20130719BHEP Ipc: A61K 31/7105 20060101ALI20130719BHEP Ipc: A61P 1/04 20060101ALI20130719BHEP |
|
17Q | First examination report despatched |
Effective date: 20140311 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R003 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED |
|
18R | Application refused |
Effective date: 20151002 |